{
    "info": {
        "nct_id": "NCT03141671",
        "official_title": "Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)",
        "inclusion_criteria": "* Histologically confirmed prostate cancer\n* PSA ≥ 0.1 after radical prostatectomy (value w/in 3 months of registration) AND at least 1 unfavorable risk factor listed below.\n\n  * Gleason 8-10\n  * PSA > 0.5\n  * Pathologically positive lymph nodes\n  * pT3 or pT4\n  * PSA doubling time (DT) < 10 months\n  * Negative margins\n  * Persistent PSA after RP (PSA never dropped below 0.1 after RP)\n  * Local/regional recurrence on imaging\n  * Decipher \"High risk\" (a Medicare-reimbursed test for risk of metastases after prostatectomy)\n* Candidate for salvage radiation and ADT treatment\n* Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. Subject must have the ability to understand and willingness to sign the written informed consent document.\n* 18 ≤ Age ≤ 95 at the time of consent\n* ECOG Performance Status ≤ 2 (Appendix A)\n* Demonstrate adequate organ function as defined in the table below. All screening labs to be obtained within 3 months of registration.\n* System Laboratory Value\n* Hematological:\n\n  * Platelet count (plt) ≥ 100,000/ µL\n  * Hemoglobin (Hgb) ≥ 9 g/dL\n  * Absolute neutrophil count (ANC) ≥ 1000 cells/µL\n* Renal:\n\n  --GFR1 ≥ 45 mL/min\n* Hepatic and Other:\n\n  * Bilirubin2 ≤ 1.5 × upper limit of normal (ULN)\n  * Aspartate aminotransferase (AST) ≤ 2.5 × ULN\n  * Alanine aminotransferase (ALT) ≤ 2.5 × ULN\n  * Serum Albumin > 3.0 g/dL\n  * Serum potassium ≥ 3.5 mmol/L\n* Coagulation:\n\n  * International Normalized Ratio (INR)\n  * or Prothrombin Time (PT)\n* Activated Partial Thromboplastin Time\n\n  * (aPTT) ≤ 1.5 × ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin)\n  * Cockcroft-Gault formula will be used to calculate creatinine clearance (see study procedure manual SPM)\n  * In subjects with Gilbert's syndrome, if total bilirubin is >1.5 × ULN, measure direct and indirect bilirubin; if direct bilirubin is ≤1.5 × ULN, subject may be eligible\n* Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential OR agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug.\n* Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug.\n* Ability to understand and comply with study procedures for the entire length of the study as determined by the site investigator or protocol designee\n* Medications known to lower the seizure threshold (see list under prohibited meds) must be discontinued or substituted at least 4 weeks prior to study entry (Section 5.5)\n* Use of CYP3A4 inhibitors or inducers and CYP2D6 substrates must be discontinued prior to study entry\n* Able to swallow pills\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 95 Years",
        "exclusion_criteria": "* Use of post-prostatectomy ADT for > 30 continuous days prior to registration (ADT defined as use of GnRH agonist, with or without an anti-androgen). However, patients with testosterone recovery after post-prostatectomy ADT are eligible (testosterone recovery defined as total testosterone > 190 ng/dL) regardless of how long they have been on ADT.\n* Prior pelvic radiation unless additional radiation can be safely delivered according to the treating physician\n* PSA > 15 ng/mL in screening\n* History of any of the following:\n\n  * Seizure or known condition that may predispose to seizure (e.g., prior stroke within 1 year of randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy)\n  * Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization\n* Current evidence of any of the following:\n\n  * Uncontrolled hypertension\n  * Gastrointestinal disorder affecting absorption\n  * Active infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis)\n  * Any chronic medical condition requiring a dose of corticosteroid higher than 10 mg prednisone/prednisolone once daily\n  * Any condition that, in the opinion of the site investigator, would preclude participation in this study\n  * Moderate or severe hepatic impairment (Child Pugh Class B or C)\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, psychiatric illness or social situations that would limit compliance with study requirements\n* Individuals with a history of another malignancy are not eligible if:\n\n  * the cancer is under active treatment or\n  * the cancer can be seen on radiology scans or\n  * if they are off cancer treatment but in the opinion of their oncologist have a high risk of relapse within 5 years\n* Confirmed bone metastases on imaging",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Absolute neutrophil count (ANC) ≥ 1000 cells/µL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1000 cells/µL",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "cells/µL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum Albumin > 3.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Serum Albumin > 3.0 g/dL",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 95 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 95 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 95,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "--GFR1 ≥ 45 mL/min",
            "criterions": [
                {
                    "exact_snippets": "GFR1 ≥ 45 mL/min",
                    "criterion": "GFR1",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed prostate cancer",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed prostate cancer",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation_method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG Performance Status ≤ 2 (Appendix A)",
            "criterions": [
                {
                    "exact_snippets": "ECOG Performance Status ≤ 2",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative margins",
            "criterions": [
                {
                    "exact_snippets": "Negative margins",
                    "criterion": "surgical margins",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilirubin2 ≤ 1.5 × upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin2 ≤ 1.5 × upper limit of normal (ULN)",
                    "criterion": "bilirubin2 level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "× ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum potassium ≥ 3.5 mmol/L",
            "criterions": [
                {
                    "exact_snippets": "Serum potassium ≥ 3.5 mmol/L",
                    "criterion": "serum potassium",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3.5,
                                "unit": "mmol/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Demonstrate adequate organ function as defined in the table below. All screening labs to be obtained within 3 months of registration.",
            "criterions": [
                {
                    "exact_snippets": "Demonstrate adequate organ function as defined in the table below.",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": "as defined in the table below"
                        }
                    ]
                },
                {
                    "exact_snippets": "All screening labs to be obtained within 3 months of registration.",
                    "criterion": "screening laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months before registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of CYP3A4 inhibitors or inducers and CYP2D6 substrates must be discontinued prior to study entry",
            "criterions": [
                {
                    "exact_snippets": "Use of CYP3A4 inhibitors or inducers ... must be discontinued prior to study entry",
                    "criterion": "CYP3A4 inhibitors or inducers use",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation before study entry",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of ... CYP2D6 substrates must be discontinued prior to study entry",
                    "criterion": "CYP2D6 substrates use",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation before study entry",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* In subjects with Gilbert's syndrome, if total bilirubin is >1.5 × ULN, measure direct and indirect bilirubin; if direct bilirubin is ≤1.5 × ULN, subject may be eligible",
            "criterions": [
                {
                    "exact_snippets": "subjects with Gilbert's syndrome",
                    "criterion": "Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "total bilirubin is >1.5 × ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "measure direct and indirect bilirubin",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "measurement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "measure direct and indirect bilirubin",
                    "criterion": "indirect bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "measurement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "direct bilirubin is ≤1.5 × ULN",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* pT3 or pT4",
            "criterions": [
                {
                    "exact_snippets": "pT3 or pT4",
                    "criterion": "pathological tumor stage (pT)",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "pT3",
                                "pT4"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PSA > 0.5",
            "criterions": [
                {
                    "exact_snippets": "PSA > 0.5",
                    "criterion": "PSA",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 0.5,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to understand and comply with study procedures for the entire length of the study as determined by the site investigator or protocol designee",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand ... study procedures",
                    "criterion": "ability to understand study procedures",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Ability to ... comply with study procedures for the entire length of the study",
                    "criterion": "ability to comply with study procedures for the entire length of the study",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "as determined by the site investigator or protocol designee",
                    "criterion": "determination by site investigator or protocol designee",
                    "requirements": [
                        {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Coagulation:",
            "criterions": [
                {
                    "exact_snippets": "Coagulation:",
                    "criterion": "coagulation",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "to be specified (coagulation parameters)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Candidate for salvage radiation and ADT treatment",
            "criterions": [
                {
                    "exact_snippets": "Candidate for salvage radiation",
                    "criterion": "salvage radiation therapy candidacy",
                    "requirements": [
                        {
                            "requirement_type": "candidacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Candidate for ... ADT treatment",
                    "criterion": "androgen deprivation therapy (ADT) candidacy",
                    "requirements": [
                        {
                            "requirement_type": "candidacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. Subject must have the ability to understand and willingness to sign the written informed consent document.",
            "criterions": [
                {
                    "exact_snippets": "Written informed consent ... prior to registration",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "HIPAA authorization for release of personal health information prior to registration",
                    "criterion": "HIPAA authorization for release of personal health information",
                    "requirements": [
                        {
                            "requirement_type": "obtained",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "Subject must have the ability to understand",
                    "criterion": "ability to understand informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign the written informed consent document",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PSA ≥ 0.1 after radical prostatectomy (value w/in 3 months of registration) AND at least 1 unfavorable risk factor listed below.",
            "criterions": [
                {
                    "exact_snippets": "PSA ≥ 0.1 after radical prostatectomy (value w/in 3 months of registration)",
                    "criterion": "PSA level after radical prostatectomy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.1,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 3 months of registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Renal:",
            "criterions": [
                {
                    "exact_snippets": "Renal:",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "criterion heading only; no specific requirement stated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pathologically positive lymph nodes",
            "criterions": [
                {
                    "exact_snippets": "Pathologically positive lymph nodes",
                    "criterion": "lymph nodes",
                    "requirements": [
                        {
                            "requirement_type": "pathological positivity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) ≤ 2.5 × ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ≤ 2.5 × ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count (plt) ≥ 100,000/ µL",
            "criterions": [
                {
                    "exact_snippets": "Platelet count (plt) ≥ 100,000/ µL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/ µL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Able to swallow pills",
            "criterions": [
                {
                    "exact_snippets": "Able to swallow pills",
                    "criterion": "ability to swallow pills",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PSA doubling time (DT) < 10 months",
            "criterions": [
                {
                    "exact_snippets": "PSA doubling time (DT) < 10 months",
                    "criterion": "PSA doubling time",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Persistent PSA after RP (PSA never dropped below 0.1 after RP)",
            "criterions": [
                {
                    "exact_snippets": "Persistent PSA after RP (PSA never dropped below 0.1 after RP)",
                    "criterion": "PSA level after radical prostatectomy (RP)",
                    "requirements": [
                        {
                            "requirement_type": "persistence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "minimum value after RP",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.1,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International Normalized Ratio (INR)",
            "criterions": [
                {
                    "exact_snippets": "International Normalized Ratio (INR)",
                    "criterion": "International Normalized Ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (aPTT) ≤ 1.5 × ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin)",
            "criterions": [
                {
                    "exact_snippets": "(aPTT) ≤ 1.5 × ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin)",
                    "criterion": "activated partial thromboplastin time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless on prophylactic or therapeutic dosing with low molecular weight heparin"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential OR agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential",
                    "criterion": "contraception use during sex with woman of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "condom use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "use of another effective method of birth control",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug",
                    "criterion": "condom use during sex with pregnant woman",
                    "requirements": [
                        {
                            "requirement_type": "condom use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during study drug"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* System Laboratory Value",
            "criterions": [
                {
                    "exact_snippets": "System Laboratory Value",
                    "criterion": "system laboratory value",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug.",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "agreement to abstain",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of abstinence",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 3,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cockcroft-Gault formula will be used to calculate creatinine clearance (see study procedure manual SPM)",
            "criterions": [
                {
                    "exact_snippets": "Cockcroft-Gault formula will be used to calculate creatinine clearance",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* or Prothrombin Time (PT)",
            "criterions": [
                {
                    "exact_snippets": "Prothrombin Time (PT)",
                    "criterion": "Prothrombin Time (PT)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Activated Partial Thromboplastin Time",
            "criterions": [
                {
                    "exact_snippets": "Activated Partial Thromboplastin Time",
                    "criterion": "activated partial thromboplastin time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "measurement",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hematological:",
            "criterions": [
                {
                    "exact_snippets": "Hematological:",
                    "criterion": "hematological parameters",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "to be specified (no specific requirement given in this line)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* 18 ≤ Age ≤ 95 at the time of consent",
            "criterions": [
                {
                    "exact_snippets": "18 ≤ Age ≤ 95 at the time of consent",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 95,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Local/regional recurrence on imaging",
            "criterions": [
                {
                    "exact_snippets": "Local/regional recurrence on imaging",
                    "criterion": "local/regional recurrence",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "imaging"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Decipher \"High risk\" (a Medicare-reimbursed test for risk of metastases after prostatectomy)",
            "criterions": [
                {
                    "exact_snippets": "Decipher \"High risk\" (a Medicare-reimbursed test for risk of metastases after prostatectomy)",
                    "criterion": "Decipher test result",
                    "requirements": [
                        {
                            "requirement_type": "risk category",
                            "expected_value": "High risk"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) ≤ 2.5 × ULN",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ≤ 2.5 × ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Gleason 8-10",
            "criterions": [
                {
                    "exact_snippets": "Gleason 8-10",
                    "criterion": "Gleason score",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 8,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 10,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Medications known to lower the seizure threshold (see list under prohibited meds) must be discontinued or substituted at least 4 weeks prior to study entry (Section 5.5)",
            "criterions": [
                {
                    "exact_snippets": "Medications known to lower the seizure threshold ... must be discontinued or substituted at least 4 weeks prior to study entry",
                    "criterion": "use of medications known to lower the seizure threshold",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation or substitution",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks prior to study entry"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin (Hgb) ≥ 9 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin (Hgb) ≥ 9 g/dL",
                    "criterion": "hemoglobin (Hgb) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* PSA > 15 ng/mL in screening",
            "criterions": [
                {
                    "exact_snippets": "PSA > 15 ng/mL in screening",
                    "criterion": "PSA",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 15,
                                "unit": "ng/mL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Moderate or severe hepatic impairment (Child Pugh Class B or C)",
            "criterions": [
                {
                    "exact_snippets": "Moderate or severe hepatic impairment (Child Pugh Class B or C)",
                    "criterion": "hepatic impairment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        },
                        {
                            "requirement_type": "Child Pugh class",
                            "expected_value": [
                                "B",
                                "C"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Severe or unstable angina ... within 6 months prior to randomization",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "severe",
                                "unstable"
                            ]
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction ... within 6 months prior to randomization",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "occurrence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure ... within 6 months prior to randomization",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks) ... within 6 months prior to randomization",
                    "criterion": "arterial or venous thromboembolic events",
                    "requirements": [
                        {
                            "requirement_type": "occurrence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant ventricular arrhythmias within 6 months prior to randomization",
                    "criterion": "ventricular arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Confirmed bone metastases on imaging",
            "criterions": [
                {
                    "exact_snippets": "Confirmed bone metastases on imaging",
                    "criterion": "bone metastases",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "imaging"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Individuals with a history of another malignancy are not eligible if:",
            "criterions": [
                {
                    "exact_snippets": "history of another malignancy",
                    "criterion": "history of another malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior pelvic radiation unless additional radiation can be safely delivered according to the treating physician",
            "criterions": [
                {
                    "exact_snippets": "Prior pelvic radiation unless additional radiation can be safely delivered according to the treating physician",
                    "criterion": "prior pelvic radiation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "if additional radiation can be safely delivered according to the treating physician"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis)",
            "criterions": [
                {
                    "exact_snippets": "Active infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis)",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs",
            "criterions": [
                {
                    "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs",
                    "criterion": "allergic reactions to compounds of similar chemical or biologic composition to study drugs",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* the cancer is under active treatment or",
            "criterions": [
                {
                    "exact_snippets": "the cancer is under active treatment",
                    "criterion": "cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "under active treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of any of the following:",
            "criterions": [
                {
                    "exact_snippets": "History of any of the following",
                    "criterion": "history of specified conditions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* if they are off cancer treatment but in the opinion of their oncologist have a high risk of relapse within 5 years",
            "criterions": [
                {
                    "exact_snippets": "off cancer treatment",
                    "criterion": "cancer treatment status",
                    "requirements": [
                        {
                            "requirement_type": "off treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of their oncologist have a high risk of relapse within 5 years",
                    "criterion": "risk of cancer relapse within 5 years",
                    "requirements": [
                        {
                            "requirement_type": "risk level",
                            "expected_value": "high"
                        },
                        {
                            "requirement_type": "assessment source",
                            "expected_value": "opinion of their oncologist"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current evidence of any of the following:",
            "criterions": [
                {
                    "exact_snippets": "Current evidence of any of the following",
                    "criterion": "evidence of listed conditions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of post-prostatectomy ADT for > 30 continuous days prior to registration (ADT defined as use of GnRH agonist, with or without an anti-androgen). However, patients with testosterone recovery after post-prostatectomy ADT are eligible (testosterone recovery defined as total testosterone > 190 ng/dL) regardless of how long they have been on ADT.",
            "criterions": [
                {
                    "exact_snippets": "Use of post-prostatectomy ADT for > 30 continuous days prior to registration",
                    "criterion": "post-prostatectomy ADT use",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "ADT defined as use of GnRH agonist, with or without an anti-androgen",
                    "criterion": "ADT definition",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "GnRH agonist",
                                "GnRH agonist with anti-androgen"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with testosterone recovery after post-prostatectomy ADT are eligible (testosterone recovery defined as total testosterone > 190 ng/dL)",
                    "criterion": "testosterone recovery after post-prostatectomy ADT",
                    "requirements": [
                        {
                            "requirement_type": "total testosterone",
                            "expected_value": {
                                "operator": ">",
                                "value": 190,
                                "unit": "ng/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, psychiatric illness or social situations that would limit compliance with study requirements",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "ongoing or active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "ongoing",
                                "active"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "social situations that would limit compliance with study requirements",
                    "criterion": "social situation limiting compliance",
                    "requirements": [
                        {
                            "requirement_type": "effect on compliance",
                            "expected_value": "limits compliance with study requirements"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Seizure or known condition that may predispose to seizure (e.g., prior stroke within 1 year of randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy)",
            "criterions": [
                {
                    "exact_snippets": "Seizure",
                    "criterion": "seizure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known condition that may predispose to seizure",
                    "criterion": "condition predisposing to seizure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior stroke within 1 year of randomization",
                    "criterion": "prior stroke",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "brain arteriovenous malformation",
                    "criterion": "brain arteriovenous malformation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Schwannoma",
                    "criterion": "Schwannoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "meningioma",
                    "criterion": "meningioma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy",
                    "criterion": "benign CNS or meningeal disease requiring surgery or radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "potential need for treatment",
                            "expected_value": [
                                "surgery",
                                "radiation therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* the cancer can be seen on radiology scans or",
            "criterions": [
                {
                    "exact_snippets": "the cancer can be seen on radiology scans",
                    "criterion": "cancer visibility on radiology scans",
                    "requirements": [
                        {
                            "requirement_type": "visibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Gastrointestinal disorder affecting absorption",
            "criterions": [
                {
                    "exact_snippets": "Gastrointestinal disorder affecting absorption",
                    "criterion": "gastrointestinal disorder",
                    "requirements": [
                        {
                            "requirement_type": "affecting absorption",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any condition that, in the opinion of the site investigator, would preclude participation in this study",
            "criterions": [
                {
                    "exact_snippets": "Any condition that, in the opinion of the site investigator, would preclude participation in this study",
                    "criterion": "any condition precluding participation (per investigator judgment)",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": "would preclude participation in this study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any chronic medical condition requiring a dose of corticosteroid higher than 10 mg prednisone/prednisolone once daily",
            "criterions": [
                {
                    "exact_snippets": "Any chronic medical condition requiring a dose of corticosteroid higher than 10 mg prednisone/prednisolone once daily",
                    "criterion": "chronic medical condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring a dose of corticosteroid higher than 10 mg prednisone/prednisolone once daily",
                    "criterion": "corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg prednisone/prednisolone once daily"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Hepatic and Other:",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}